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Abstract
Introduction Patients with bone metastases often experi-
ence skeletal-related events (SREs). Although cost-utility
models are used to examine treatments for metastatic
cancer, limited information is available on utilities of
SREs. The purpose of this study was to estimate the dis-
utility of four SREs: spinal cord compression, pathological
fracture, radiation to bone, and surgery performed to sta-
bilize a bone.
Methods General population participants from the UK
and Canada completed time trade-off (TTO) interviews to
assess the utility of health states drafted based on literature
review, clinician interviews, and patient interviews.
Respondents first rated a health state describing cancer
with bone metastases. Then, the SREs were added to this
health state.
Results Interviews were completed with 187 participants
(50.8 % male, 80.2 % white). Cancer with bone metastases
without an SRE had a mean utility of 0.47 (SD = 0.43) on
a standard utility scale (1 = full health, 0 = death). Of the
SREs, spinal cord compression was associated with the
greatest disutility (i.e., the utility decrease): -0.32 with
paralysis and -0.22 without paralysis. Surgery had a dis-
utility of -0.07. Leg, arm, and rib fractures had disutilities
of -0.06, -0.04, and -0.03. Two weeks of daily radiation
treatment had a disutility of -0.06, while two radiation
appointments had the smallest impact on utility (-0.02).
Conclusion All SREs were associated with statistically
significant utility decreases, suggesting a perceived impact
on quality of life beyond the impact of cancer with
bone metastases. The resulting disutilities may be used in
cost-utility models examining treatments to prevent SREs
secondary to bone metastases.
Keywords Utility  Skeletal-related events  Bone
metastases  Cancer  Cost-utility  Time trade-off
Introduction
The skeleton is one of the most common sites of metastatic
disease among adults with breast, prostate, lung, thyroid,
and kidney cancers [1, 2]. Bone metastases are associated
with poor outcomes, including persistent pain and
decreased survival [3]. Furthermore, the spread of cancer
cells to the bone results in excessive bone turnover and
extensive bone destruction, which leads to skeletal com-
plications, collectively referred to as skeletal-related events
(SREs). SREs include pathological fractures, spinal cord
compression, surgery to the bone, and radiation to bone
[1, 4–7]. In many cases, these SREs can be severely
debilitating, resulting in a profound decrease in health-
related quality of life (HRQL) [8, 9].
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As new treatments are developed for patients who are at
risk for SREs, it is important to evaluate their cost-effec-
tiveness in order to demonstrate their value to patients,
clinicians, and third-party payers. A cost-utility analysis
(CUA) is a type of cost-effectiveness analysis that incor-
porates the preferences of individuals for different treat-
ment-related outcomes [10, 11]. These preferences are
quantified in terms of utilities, which are values repre-
senting health status and HRQL on a scale with anchors of
0 representing states as undesirable as being dead and 1
representing full health [12–14]. Because SREs have a
significant effect on HRQL [9], they are likely to have an
impact on utility and the outcome of a cost-utility analysis.
However, little is known about the disutility (i.e., the
utility decrease) associated with individual types of SREs.
Although previous research has estimated utilities associ-
ated with SREs, these studies have often provided utility
estimates for only one or two types of SREs, such as
radiation or fracture [9, 15, 16]. Other previous studies
have provided utility estimates associated with SREs as a
general group, without differentiating among types of
SREs [17, 18]. The resulting lack of clarity on the disutility
associated with each type of SRE limits the usefulness of
these data in economic models. Therefore, the purpose of
the current study was to identify the impact of individual
types of SREs on health state utility, using time trade-off
(TTO) interviews with general population respondents in
the UK and Canada.
Methods
Development of health states
The health state vignettes representing cancer with bone
metastases and SREs were drafted based on literature review
and telephone interviews with clinicians and patients. First, a
literature review was conducted to identify studies of bone
metastases and SREs to ensure that the health states would be
grounded in clinical research [3, 9, 19–24]. Information
obtained from this literature search was used when drafting
structured interview guides for the patient and clinician
interviews.
Interviews were conducted with eight medical profes-
sionals who had direct experience working with patients
who had experienced SREs. Six of the respondents were
medical oncologists, one was a radiation oncologist, and
one was an acute care nurse practitioner working at a
hematology/oncology clinic. Interviews were first con-
ducted to inform health state development. After the health
states were drafted, the same respondents were interviewed
again to assess the health states’ clarity and accuracy, and
minor revisions were made as a result.
Interviews were also conducted with 11 patients
recruited from three clinical oncology sites. All patients
had breast (six female patients) or prostate (five male
patients) cancer, as well as confirmed radiologic evidence
of bone metastases. All had experienced at least one of the
four SREs within four months of the recruitment screening
date. Three patients had experienced a spinal cord com-
pression. Six had experienced pathological fractures
(including fractures of the knee, vertebrae, and right clav-
icle). Ten had received radiation therapy to the bone, and
three had surgery to the bone. The interviewers followed a
semi-structured interview guide focusing on patients’
experiences with SREs. The language patients used to
describe their symptoms and treatment was incorporated
into the health states.
Health states were tested in a pilot study with 19
members of the general population (13 female; mean
age = 59.0 years) recruited through a newspaper adver-
tisement. The draft health states were administered in a
TTO interview to ensure that respondents were able to
understand the health states and the interview task. All
participants reported that the health states were clear and
easy to understand. Some participants suggested minor
revisions in formatting and phrasing, and the health states
were edited accordingly.
Final health states administered in the time trade-off
interview
The final set of health state vignettes included a ‘‘basic
health state’’ (health state A), which was designed to rep-
resent a patient with cancer and bone metastases, but
without an SRE. This health state included the following
statements: ‘‘You have cancer that has spread to your bone.
In parts of your body where the cancer has spread, the
cancer can weaken your bones. You have pain where the
cancer has spread to the bone. This pain is aching and
present most of the time. The pain increases with move-
ment, and it may interfere with your daily activities. Your
cancer requires treatment such as hormone therapy or
chemotherapy. Hormone therapy may have side effects
such as hot flashes and decreased sex drive. Chemotherapy
may have side effects such as hair loss, nausea, and
fatigue.’’
An additional eight health states (health states B to I)
included this basic health state, followed by 4–6 statements
describing an SRE, as well as its duration and impact on
functioning (the full health state text is presented in the
‘‘Appendix’’). The eight health states were designed to
represent the four SREs: (1) spinal cord compression;
(2) pathological fracture; (3) radiation to bone to manage
complications such as uncontrolled bone pain or impending
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fracture; and (4) surgery for bone complications including
fractures or potential fractures [3, 19, 21].
Spinal cord compression was represented by two health
states describing a compression without (Health State B)
and with (C) paralysis because these two types of com-
pression have a dramatically different impact on mobility
and quality of life. There were three health states
describing pathological fractures of the leg (D), rib (E), and
arm (F). These three locations were chosen to represent
mild (rib), moderate (arm), and severe (leg) fractures in
terms of their impact on pain and mobility. Radiation was
represented by two health states describing two possible
courses of radiation treatment: daily radiation over a
2-week period (G) and radiation occurring in only two
appointments (H). Two treatment courses were included
because clinician interviews indicated that duration of
radiation treatment tends to vary across geographical
regions. Surgery was represented by a health state
describing a surgical procedure to stabilize a bone in the
leg that had weakened due to the cancer (I). This type of
surgery was selected based on clinician input and published
literature indicating that pathological fractures tend to
occur most frequently in weight-bearing bones such as the
femur, and these fractures require surgery to stabilize the
bone, reduce pain, and help restore mobility [24].
Participants in the valuation survey
Because the valuations of health states were intended to
yield utilities that may be used in submissions to agencies
like National Institute for Health and Clinical Excellence
(NICE), most of whom require general population values,
the inclusion criteria did not specify any particular clinical
characteristics. All participants were required to be at least
18 years old; understand the assessment procedures; and
reside in the United Kingdom or Canada.
In the UK, participants were recruited through news-
paper advertisements in Edinburgh and London in July
2010. In Canada, participants were recruited through
advertisements in Montre´al in September 2010 and
Toronto in December 2010. In the UK, a total of 592
potential participants responded to the advertisements by
leaving a telephone message, and 179 of these were
reached for screening to assess whether they met study
inclusion criteria (i.e., 179 participants answered the phone
when called by project staff). Of the 179 screened partic-
ipants, all were eligible, 147 were available to be scheduled
for interviews, 130 participants attended interviews, and
126 of these participants were able to complete the TTO
interview. In Canada, a total of 523 potential participants
responded, and 105 were reached for screening. Of the
105 potential participants who were screened, 102 were
eligible, 74 were scheduled, 63 attended the interview, and
61 were able to complete the TTO interview.
Utility interview procedures and scoring
The utility interview began with a visual analogue scale
(VAS) that was intended to introduce participants to the
health states. Health states were presented to each partici-
pant on individual cards, and each was rated relative to
anchor states of zero (dead) and 100 (full health). Then,
health state utilities were obtained using the TTO method,
which has previously been described in detail [25]. The
TTO assessments of health state utilities are often con-
ducted using a 10-year time frame, as this time frame was
used in the Measurement and Valuation of Health (MVH)
study to elicit valuations from the general public for
EQ-5D health states [26]. However, other time frames may
be used, depending on what is most appropriate for the
medical condition under examination. For the current
study, a 2-year time frame was used so that the impact of
the SREs would be judged within the context of a realistic
life expectancy for a patient with advanced cancer and
bone metastases.
In the TTO task, participants were first presented with
the basic health state (health state A) and offered a choice
between spending two years in this health state versus
spending varying shorter amounts of time in the full health
state, followed by death. After rating Health State A, par-
ticipants were presented with each of the SRE health states
(Health States B–I) in random order. For each of these SRE
health states, participants were told to consider a lifespan
of two years in Health State A, with the SRE occurring
roughly in the middle of the 2-year time period. Respon-
dents were told that the SRE occurred roughly in the
middle of the 2-year lifespan in order to avoid potential
biases stemming from reluctance to experience the SRE
immediately or at the end of one’s life. Participants con-
cluded the TTO task by rating their own current health
state.
For each health state rated as preferable to being dead in
the TTO task, the utility value is calculated based on the
choice in which the respondent is indifferent between
y months in the health state being evaluated and x months
in full health (followed by y–x months dead). The resulting
utility estimate (u) is calculated by setting to equal the
expected value of the two options [1* x ? 0 * (y –
x) = u * y], and then rearranging to solve for u (u = x/y).
In the current study, y is two years.
If participants indicated that a health state was worse
than dead, the interviewer altered the task so that respon-
dents were offered a choice between immediate death
(alternative 1) and a 2-year life span (alternative 2)
beginning with varying amounts of time in the health state
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being rated, followed by full health for the remainder of the
two years. For TTO ratings of health states considered
worse than death, two scoring approaches have been used
in previous studies, as described by Brazier et al. [25]. The
first approach, which is based on the choice in which the
respondent is indifferent between the two alternatives,
yields utilities with a possible range of 0 to -?. These
unbounded negative values have a strong tendency to skew
the overall distribution of utility estimates for any health
states that are rated as worse than dead by even a small
number of respondents. Therefore, the current study used
an alternative bounded scoring approach, which is com-
monly used to avoid highly skewed distributions. This
approach limits the range of utilities for health states worse
than death so that scores are between 0 and -1. To com-
pute these bounded negative utility values, the current
study used the Dolan [46] method as described by Rowen
and Brazier [34]. This method uses the formula ‘‘-x/t’’,
where x is the number of months in full health, and t is the
total life span of alternative 2 in the TTO choice. In the
current study, t is 24 months, which is the number of
months in the health state being rated plus subsequent
months in full health.
The purpose of this study was not only to identify the
utilities of various health states, but also to identify the
disutility associated with each specific SRE. The disutility
of each SRE was calculated as the difference between the
utility of the basic health state (metastatic cancer without
an SRE) and the utility of the otherwise identical health
states with an added SRE. Calculating differences between
health states to identify disutilities of specific attributes has
been shown to be useful in other utility studies [27, 28].
RAND-36
The RAND Health Survey 36-item short form (RAND-36)
was administered for use in analyses assessing the validity
of the utility procedure by comparing the RAND-36 score
to the utility score for the participant’s own current health.
The RAND-36 consists of 36 items contributing to eight
scales: physical functioning, social functioning, role limi-
tations due to physical health problems, role limitations
due to emotional problems, pain, mental health, vitality,
and general health perceptions [29].
Data collection and statistical analysis procedures
Interviews were conducted in Edinburgh and London
during August 2010, as well as in Montre´al and Toronto
from September 2010 to January 2011. All procedures and
instruments were approved by an independent Institutional
Review Board, and all participants provided written
informed consent. Statistical analyses were completed using
SAS version 8.12 (SAS Institute, Cary, NC). Continuous vari-
ables including utilities are summarized in terms of means and
standard deviations, and categorical variables such as gender
and race are summarized as frequencies and percentages.
The disutility of each SRE was calculated by subtracting
the utility of each SRE health state (B–I) from the utility of
health state A. This disutility quantifies the impact of the
SRE on a 2-year life span, which was the timeframe of the
TTO task in the current study. These disutilities may be
used to compute the impact of SREs on quality-adjusted
life years (QALYs), which are used to quantify outcomes in a
cost-utility analysis so that treatments may be compared in
terms of cost per QALY gained. The QALY is a general
measure of health outcomes that incorporates both quality of
life and quantity of life, with quality defined in terms of util-
ities and quantity defined in terms of years [11, 30–32].
To demonstrate the impact of each type of SRE on
QALYs, the overall QALY decrement associated with each
SRE was calculated for the combined UK/Canada sample.
Because the disutility values in the current study represent
the impact of an SRE on a 2-year lifespan, the disutility
should be applied throughout a 2-year period of a cost-
utility model when modeling a patient who experiences an
SRE (i.e., subtracting the disutility from a patient’s utility
value for both of these two years). For example, an SRE
with a disutility of -0.10 would be applied for two years of
the patient’s life, resulting in a total QALY decrement of
-0.20 over the 2-year period. Therefore, the total QALY
decrement associated with each SRE can be computed by
doubling the disutility value resulting from the current
TTO task.
Spearman’s correlations between the TTO utilities for
current health and the RAND-36 subscale scores were
performed to assess validity of the TTO procedure. Cor-
relation coefficients were interpreted based on Cohen’s
[33] guidelines suggesting that a coefficient of 0.10–0.29 is
small, 0.30–0.49 is moderate, and greater than 0.50 is large.
To examine differences among health states, paired t-tests
were conducted to assess whether differences between key
pairs of health states were statistically significant. Statis-
tical significance was considered to be p \ 0.05.
Results
Sample description
A total of 187 participants completed the utility interview
(Table 1). The sample was almost evenly divided between
men and women (49.2 % female), and the mean age was
46.1 years. A majority of the sample reported their eth-
nicity as being white (80.2 %), and 38.5 % reported being
currently married. Almost half of the sample were
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employed full-time (n = 82; 43.9 %), and the majority
completed a college or university degree (n = 115;
61.5 %). When asked to report health conditions, over half
the sample reported none (n = 113, 60.4 %). The most
commonly reported health conditions were depression
(n = 19, 10.2 %) and arthritis (n = 16, 8.6 %). Only
3.2 % of the total sample (n = 6) reported that they had a
diagnosis of cancer at any time in their lives, and no par-
ticipants reported cancer that had metastasized to the bone.
Demographic characteristics are also presented sepa-
rately for the UK and Canadian sub-samples (Table 1).
There were no statistically significant differences between
the two sub-samples in age, gender, marital status, or
education level. There was a statistically significant dif-
ference in racial/ethnic background (p \ 0.05). Although
both samples were predominantly white, the UK sample
had a greater proportion of white participants. Addition-
ally, a greater proportion of the Canadian sample was
employed full-time (59.0 vs. 36.5 %; p \ 0.05).
Descriptive statistics: utilities
The VAS scores and TTO utilities for all health states are
presented in Tables 2 and 3, respectively. In the total
sample, the basic health state (A) describing cancer with
bone metastases without an SRE had a mean VAS score of
38.5 and a TTO utility of 0.47. For the eight health states
that included an SRE (health states B–I), mean VAS scores
ranged from 1.0 to 31.7, and mean TTO utilities ranged
from 0.15 to 0.45. The t tests comparing the UK and
Canadian samples found no significant differences in util-
ities for any of these health states (p = 0.46–0.99). The
mean utility for respondents’ own current health was 0.94,
which is reflective of a healthy general population sample.
The disutility of each SRE was computed by subtracting
the utility of each SRE health state from the utility of
health state A, which is an otherwise identical health state
without an SRE (Table 4). The SRE disutilities ranged
from -0.02 for two radiation appointments to -0.32 for
spinal cord compression with paralysis. The smallest
disutilities were for milder SREs including two radiation
appointments (disutility = -0.02), and pathological frac-
tures of the rib and arm (-0.03 and -0.04, respectively).
Two weeks of radiation treatment (-0.06), pathological
fracture of the leg (-0.06), and surgery (-0.07) were
associated with a larger disutility, while spinal cord com-
pression was associated with the greatest disutility of all
the SREs (-0.22 without paralysis and -0.32 with paral-
ysis). There were no significant differences in disutilities
between the samples in the UK and Canada (p = 0.27 to
0.97). These disutilities represent the impact of each SRE
on preferences for the 2-year life span in the current TTO
Table 1 Demographic characteristics
Characteristics UK
(N = 126)
Canada
(N = 61)
Total sample:
UK and Canada
(N = 187)
Age (mean, SD) 45.4 (16.0) 47.7 (9.9) 46.1 (14.3)
Gender (n, %)
Male 65 (51.6 %) 30 (49.2 %) 95 (50.8 %)
Female 61 (48.4 %) 31 (50.8 %) 92 (49.2 %)
Ethnicity (n, %)
White 107 (84.9 %) 43 (70.5 %) 150 (80.2 %)
Black 11 (8.7 %) 6 (9.8 %) 17 (9.1 %)
Asian 3 (2.4 %) 8 (13.1 %) 11 (5.9 %)
Other 5 (4.0 %) 4 (6.6 %) 9 (4.8 %)
Marital status (n, %)
Married 49 (38.9 %) 23 (37.7 %) 72 (38.5 %)
Not married 77 (61.1 %) 38 (62.3 %) 115 (61.5 %)
Employment status (n, %)
Full-time work 46 (36.5 %) 36 (59.0 %) 82 (43.9 %)
Part-time work 34 (27.0 %) 10 (16.4 %) 44 (23.5 %)
Unemployed 10 (7.9 %) 3 (4.9 %) 13 (7.0 %)
Othera 36 (28.6 %) 12 (19.7 %) 48 (25.7 %)
Education level (n, %)
Completed college/university degree 82 (65.1 %) 33 (54.1 %) 115 (61.5 %)
Did not complete college/university degree 44 (34.9 %) 28 (45.9 %) 72 (38.5 %)
a Other includes homemaker, caregiver, student, retired, and disabled
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task. The total QALY decrement of each individual SRE
across the lifespan ranged from -0.05 to -0.63 (Table 4).
Correlations between self-reported health status
and time trade-off utility of respondent’s own current
health
Since this study was conducted with a sample from the
general population, most participants had a high TTO
utility for their own current health (mean = 0.94;
SD = 0.09; mode = 0.96 which was the utility for 135 of
the 187 participants). Despite the limited variability in
these utilities, all correlations between the TTO utility for
participants’ own current health and the scales of the
RAND-36 were in the expected direction, ranging from
0.16 to 0.36. Correlations with the following scales were
statistically significant: role limitations due to physical
health (r = 0.24; p \ 0.01), role limitations due to emo-
tional problems (r = 0.24; p \ 0.05), vitality (r = 0.20;
p \ 0.05), social functioning (r = 0.28; p \ 0.01), pain
(r = 0.23; p \ 0.05), general health (r = 0.36; p \ 0.001),
physical component summary score (r = 0.23; p \ 0.05),
and mental component summary score (r = 0.20;
p \ 0.05). Overall, these correlations indicate that higher
Table 2 Visual analog scale health state ratings
Health states UK
(N = 126)
Canada
(N = 61)
Total sample:
UK and Canada
(N = 187)
Mean SD Mean SD Mean SD
A: basic health state (cancer with bone metastases, no SRE) 42.3 25.6 30.6 16.9 38.5 23.7
B: basic HS ? spinal cord compression without paralysis 10.5 21.1 2.6 21.3 7.9 21.4
C: basic HS ? spinal cord compression with paralysis 2.5 24.0 -2.2 24.0 1.0 24.1
D: basic HS ? fracture of the leg 22.0 22.8 11.1 18.3 18.5 22.0
E: basic HS ? fracture of the rib 31.0 24.0 18.8 16.6 27.0 22.6
F: basic HS ? fracture of the arm 25.4 21.9 15.2 17.7 22.1 21.1
G: basic HS ? radiation treatment (2 weeks, 5 appointments per week) 31.1 24.1 18.2 19.3 26.9 23.4
H: basic HS ? radiation treatment (2 appointments) 35.7 24.6 23.4 16.4 31.7 22.9
I: basic HS ? surgery to stabilize bone 22.9 25.2 11.9 19.6 19.3 24.0
Own current health state 89.6 9.1 85.0 11.0 88.1 9.9
HS health state
SRE skeletal-related event
* VAS values are on a scale with anchors of 0 representing death and 100 representing full health
Table 3 Time trade-off health state utilities
Health states UK
(N = 126)
Canada
(N = 61)
Total sample:
UK and Canada
(N = 187)
Mean SD Mean SD Mean SD
A: basic health state (cancer with bone metastases, no SRE) 0.47 0.41 0.47 0.45 0.47 0.42
B: basic HS ? spinal cord compression without paralysis 0.25 0.50 0.25 0.54 0.25 0.51
C: basic HS ? spinal cord compression with paralysis 0.13 0.49 0.19 0.53 0.15 0.50
D: basic HS ? fracture of the leg 0.42 0.41 0.40 0.48 0.41 0.43
E: basic HS ? fracture of the rib 0.44 0.42 0.43 0.47 0.44 0.43
F: basic HS ? fracture of the arm 0.44 0.41 0.43 0.48 0.43 0.43
G: basic HS ? radiation treatment (2 weeks, 5 appointments per week) 0.42 0.42 0.41 0.50 0.41 0.45
H: basic HS ? radiation treatment (2 appointments) 0.45 0.41 0.45 0.45 0.45 0.42
I: basic HS ? surgery to stabilize bone 0.40 0.44 0.39 0.50 0.40 0.46
Own current health state 0.95 0.05 0.92 0.13 0.94 0.09
HS health state
SRE skeletal-related event
* TTO utilities are on a scale with anchors of 0 representing death and 1 representing full health
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TTO utilities for own participants’ current health were
associated with better health status.
Comparisons among health state utilities
Paired t tests in the total sample found that utilities of all
SRE health states (B–I) were significantly different from
the utility of health state A, which did not include an SRE
(t = 3.7 to 12.7; all p \ 0.001). The T-tests were also
conducted to examine whether utilities of similar health
states were significantly different from each other. The two
radiation health states, G (2 weeks) and H (two appoint-
ments), had significantly different mean utilities (t = -3.6;
p \ 0.001). The two spinal cord compression health states,
B (without paralysis) and C (with paralysis), also had
significantly different mean utilities (t = 7.2; p \ 0.001).
The health states representing pathological fractures of the
rib (E) and arm (F) both had significantly higher utilities
than health state D representing a leg fracture (t = -4.7
and -4.1, respectively; both p \ 0.001).
Discussion
The current study provides a more detailed assessment of
utilities associated with SREs than has previously been
available. Each of the four SREs had an impact on utility, and
there were logical statistically significant differences among
the health states. For example, respondents differentiated
between radiation treatment of different frequencies and
among three types of pathological fractures. It has been
suggested that differences among health state utilities of at
least 0.05 can be considered clinically important [30]. The
disutilities of most SREs in the current study exceeded this
threshold, indicating that SREs have an important impact on
utility. In light of these results, it is recommended that
researchers conducting cost-utility models of treatment for
bone metastases consider incorporating the disutility asso-
ciated with SREs. Furthermore, because each of the four
SREs appears to be associated with a distinct disutility, they
should be quantified individually rather than applying a
common disutility value across all SREs.
The utilities followed logical patterns. For example,
surgery had a stronger impact on utility than either radia-
tion or pathological fracture, and spinal cord compression
was associated with a substantially greater disutility than
any other SRE. Furthermore, the health state representing
radiation treatment with only two appointments had the
smallest disutility. Adding to confidence in the study pro-
cedures, the TTO utility for respondents’ own current
health was significantly associated with their self-reported
health status as represented by most scales of the RAND-
36. In sum, the logical pattern of results suggests that
respondents understood the TTO task, and the resulting
utilities adequately represent their preferences among the
health states.
Table 4 Disutilites and QALY decrease associated with skeletal-related events
Health states representing each SRE Disutility*
UK
(N = 126)
Canada
(N = 61)
Total sample: UK and Canada
(N = 187)
QALY decrement**
(N = 187)
Mean SD Mean SD Mean SD Mean SD
B: basic HS ? spinal cord compression
without paralysis
-0.22 0.31 -0.22 0.32 -0.22 0.31 -0.44 0.62
C: basic HS ? spinal cord compression
with paralysis
-0.34 0.36 -0.28 0.30 -0.32 0.34 -0.63 0.68
D: basic HS ? fracture of the leg -0.05 0.09 -0.07 0.19 -0.06 0.13 -0.11 0.26
E: basic HS ? fracture of the rib -0.03 0.08 -0.04 0.17 -0.03 0.12 -0.06 0.24
F: basic HS ? fracture of the arm -0.03 0.07 -0.04 0.17 -0.04 0.11 -0.07 0.23
G: basic HS ? radiation treatment
(2 weeks, 5 appointments per week)
-0.05 0.12 -0.06 0.21 -0.06 0.15 -0.11 0.31
H: basic HS ? radiation treatment
(2 appointments)
-0.02 0.07 -0.02 0.11 -0.02 0.08 -0.05 0.17
I: basic HS ? surgery -0.07 0.17 -0.08 0.21 -0.07 0.18 -0.15 0.37
SRE skeletal-related event
HS health state
* TTO utilities are on a scale with anchors of 0 representing death and 1 representing full health. Disutilities of each SRE are computed by
subtracting health state A (bone metastases without an SRE) from each of the other health states (bone metastases with an SRE)
** The disutility values represent the impact of each SRE on a 2-year lifespan, which was the time horizon of the TTO task in this study.
Therefore, the total QALY decrement associated with each SRE was computed by doubling the disutility value resulting from the TTO task
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Data collection for the current study was completed first in
the UK, followed by the replication in Canada. The Canadian
sample was added to provide further support for the utilities
and to examine whether the influence of SREs on preferences
would vary in a different culture and geographic location.
Although VAS ratings for each health state were lower in
Canada than in the UK, the TTO utility results were remark-
ably similar across the two countries. The consistency across
the two countries adds to confidence that the current results are
reasonable estimates of the disutility of the four SREs.
Although TTO methods yielded logical utilities, it should
be noted that other utility assessment methods are possible.
The current health states could be rated with generic multi-
attribute classification systems such as the EQ-5D, SF-6D,
and Health Utilities Index [34]. However, the generic multi-
attribute measures have some important limitations. For
example, they are unlikely to be sensitive to clinically
important aspects of health states that are not directly cap-
tured by their limited number of items and response options.
Therefore, they may not be detailed enough to reflect the
impact of specific medical conditions and treatment attri-
butes, such as those described in the current SRE health
states [34–39]. In contrast, the current TTO approach
allowed respondents to consider every aspect of the health
states when providing their responses. Furthermore, multi-
attribute measures have been shown to have ceiling and floor
effects, which makes them less sensitive to health states in
the upper or lower ends of the utility scale range [25, 35, 37,
40, 41]. Because of these limitations of generic multi-attri-
bute measures, direct utility elicitation methods were con-
sidered preferable for assessing the current health states.
Despite the strengths and logical results of this study,
several limitations of the study design should be acknowl-
edged. First, vignette-based utility assessment methods are
limited because respondents rate health states based on brief
descriptions in the vignettes, rather than direct personal
experience. Although vignettes for the current study were
carefully drafted based on published literature as well as
patient and clinician descriptions of each SRE, the accuracy
of each utility is limited by the level of detail and clarity of
the vignettes. For example, it is possible that participants
underestimated the impact of a pathological leg fracture. The
mean disutility of 0.06 may not capture the full extent of this
painful and potentially debilitating experience. Despite
efforts to accurately represent a pathological fracture, it is
possible that this health state seemed less aversive to some
respondents because a fracture is a familiar experience.
Some respondents could have been thinking of their own
experiences with bone fractures that healed relatively
quickly, instead of considering the full impact of a patho-
logical fracture experienced by a patient with bone metas-
tases. A key advantage of vignette-based utility assessment is
that it can be used to identify utilities of specific factors that
may be difficult to isolate in a patient sample. Instruments
which are designed to derive utilities from patient samples,
such as the EQ-5D or Health Utilities Index, may not have
items or response options that are sensitive to specific
medical conditions, events, or treatment attributes [42].
In contrast, health state vignettes can be designed to focus on
any specific aspect of disease or treatment that may be
important to capture in a cost-utility model. The extent to
which vignette-based utilities would correspond to utilities
derived from direct patient experience is not known.
Characteristics of the sample should also be considered
when interpreting findings. Reimbursement authorities often
prefer that cost-utility analyses use utilities derived from
general population respondents to ensure that societal values
are represented when making decisions about public funding
for medical treatment [38, 43–45]. Therefore, the current
study was conducted with a broad sample of respondents
regardless of their health status or clinical history. However,
the participants were not specifically recruited to be repre-
sentative of the general population, and it is not known
whether preferences for health states would be different in a
truly representative sample. In addition, the recruitment
strategy involving newspaper and Internet advertisements
could have introduced sample selection biases to the extent
that some potential participant groups may have less access
to these media outlets. Still, the current sample was reason-
ably diverse with regard to most demographic variables, and
there is no reason to believe their values would be system-
atically different from a nationally representative sample.
Several characteristics of the health states also suggest
that results should be interpreted with appropriate caution.
First, these health states describe a severe medical condition,
and consequently, 48 (25.7 %) of the 187 respondents rated
at least one health state as worse than being dead (26.2 % in
the UK; 24.6 % in Canada). A concern with TTO method-
ology is that health states worse than dead are rated in a
slightly different procedure than states with positive scores
(as described in the methods section), and the resulting
negative scores are on a different scale [25]. There are sev-
eral available approaches for transforming negative utilities
so that they are on the same scale as positive utilities, but no
consensus has been reached on a most widely accepted
method. The transformation approach used in the current
study was selected in order to make the values comparable to
those from the UK EQ-5D valuation study [46]. New
methods are being developed for valuing states worse than
dead, but these methods are not yet widely used [34].
Another challenge associated with these health states is that
they were developed to capture the disutility of relatively brief
events, lasting several months or less. Typical utility assess-
ment methods involving valuation of unchanging health state
vignettes would not have been appropriate for assessment of
SRE disutilities. For example, the most common time trade-off
14 L. S. Matza et al.
123
approach is to value health states lasting ten years without a
change. Clearly, SREs such as a fracture cannot be described
in an unchanging health state of this duration. To capture the
disutilities of SREs in the current study, it was necessary to
specify that the events were temporary in order to realistically
represent the temporary nature of SREs in the context of
cancer with bone metastases. However, because the health
states returned to the pre-SRE state after the temporary event,
the resulting disutilities do not capture any residual or long-
term impact of having an SRE. Some SREs have been shown
to be associated with lasting impact, such as increased pain or
analgesic use [47]. Therefore, findings may underestimate the
impact of these SREs.
When interpreting and using these disutilities for modeling,
it is important to remember that they represent the impact of a
single SRE on preferences for a two-year lifespan. There are
two possible approaches for using these disutility values in a
cost-utility analysis. One approach is to apply the disutility for
a 2-year period when modeling a patient who experiences an
SRE (i.e., subtracting the disutility from a patient’s utility
value for these two years). If the disutility value is used in this
way, the total QALY decrease across the patient’s lifespan
would be double the value of the disutility itself. For example,
to model a patient experiencing a spinal cord compression
without paralysis, the disutility of -0.22 would be applied for
two years of the patient’s life, resulting in a total QALY
decrement of -0.44 over the 2-year period. A second, and
possibly simpler, approach would be to apply a one-time
QALY decrement for each SRE that is experienced, using a
value that is double the disutility for the particular SRE. For
example, a one-time QALY decrement of -0.44 would be
used for patients expressing spinal cord compression without
paralysis. These two approaches yield mathematically
equivalent results in terms of the impact of SREs on the total
number of QALYs and the outcomes of a cost-utility model.
The two-year time frame of the TTO task may also have
implications. Although longer time horizons such as ten years
are more commonly used for TTO valuation, the two-year
time frame was selected to more accurately represent a typical
lifespan of patients with bone metastases [48]. The QALY
model is based on the assumption that the utility of a health
state is the same regardless of how long someone is in the state.
There is evidence that utilities may vary based on the time
horizon of a TTO procedure [49, 50], although some findings
suggest that this variation may be relatively small [51].
Current results provide the disutility of each individual
SRE, and it is not clear how these values may change when
modeling patients with multiple SREs in a single year. For
example, multiple SREs could be combined additively, but
this approach may not accurately represent patient expe-
riences. The SREs often occur in sequence, as single
patients may experience one SRE followed by another. It is
possible that the true impact of two SREs could be greater
or less than the sum of the two disutilities, depending on
the individual patient and the unique combination of SREs.
Despite the limitations, the current study is a step toward
more thorough modeling of treatment for patients with bone
metastases. The current disutilities may be used to compute
QALY decrements associated with SREs so that the impact
of these often debilitating events can be represented in
cost-utility analyses. Future research may further examine
and refine the disutilities of SREs, especially multiple
co-occurring SREs, among patients in clinical trials or among
larger nationally representative general population samples.
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Appendix: Health states
Health state A: basic health state (cancer with bone
metastases, no SREs)
• You have cancer that has spread to your bone.
• In parts of your body where the cancer has spread, the
cancer can weaken your bones.
• You have pain where the cancer has spread to the bone.
This pain is aching and present most of the time.
• The pain increases with movement, and it may interfere
with your daily activities.
• Your cancer requires treatment such as hormone therapy or
chemotherapy. Hormone therapy may have side effects
such as hot flashes and decreased sex drive. Chemotherapy
may have side effects such as hair loss, nausea, and fatigue.
Health state B: basic health state ? spinal cord
compression without paralysis
• Because your cancer has spread to your spinal column,
there is pressure on nerves in your spinal cord that
connect to the rest of your body.
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• The compression of nerves in your spinal column leads
to severe pain in your back. The pain also runs down
your legs and increases with abrupt motion, like with
coughing or sneezing.
• You have numbness and tingling in your legs.
• You have severe pain, which causes difficulty sleeping,
walking, and moving around.
• You sometimes have difficulty controlling bowel and
bladder function, leading to occasional incontinence.
• These issues persist for about 3 months.
Health state C: basic health state ? spinal cord
compression with paralysis
• Because your cancer has spread to your spinal column,
there is pressure on nerves in your spinal cord that
connect to the rest of your body.
• Because of the compressed nerves, you are paralyzed
below the waist.
• You have serious pain in your back, above the area of
paralysis. This pain causes difficulty sleeping.
• You cannot walk or stand by yourself. You require a
wheelchair to get around.
• You have persistent difficulty controlling bowel and
bladder function, leading to persistent fecal and urinary
incontinence.
• These issues persist for about 3 months.
Health state D: basic health state ? pathological
fracture of the leg
• Because your cancer has weakened your bone, you have
a fracture in your leg resulting from a minor impact.
• The fracture causes extreme, intense pain in your leg.
The pain becomes worse with movement and causes
difficulty sleeping.
• You cannot walk or put any weight on your leg for the
first month.
• Although the pain decreases with treatment, you
continue to have some pain and mobility problems for
about 3 months.
Health state E: basic health state ? pathological
fracture of the Rib
• Because your cancer has weakened your bone, you
have a fracture in your rib that occurred spontaneously,
without any impact.
• You have moderate pain in the area where the fracture
occurred, particularly with movement.
• The fracture causes discomfort when something
touches this area of your body.
• Although the pain decreases with treatment, you
continue to have some pain for about 3 months.
Health state F: basic health state ? pathological
fracture of the arm
• Because your cancer has weakened your bone, you
have a fracture in your arm resulting from a minor
impact.
• The fracture causes extreme, intense pain in your arm.
The pain becomes worse with movement and causes
difficulty sleeping.
• You cannot move your arm or lift any weight for the
first month.
• Although the pain decreases with treatment, you
continue to have some pain and limited use of your
arm for about 3 months.
Health state G: basic health state ? radiation treatment
(2 weeks, Five appointments per week)
• Because your pain has recently increased, you receive
radiation treatment to control cancer cell growth in your
bone and to reduce some of your bone pain.
• You attend radiation appointments 5 days per week for
2 weeks.
• Each radiation appointment lasts about 30 min. During
the procedure, you lie still and experience no pain (like
when getting an x-ray).
• In the area where you receive radiation, your skin
becomes irritated, like getting a sunburn. You also feel
fatigued after each treatment.
Health state H: basic health state ? radiation treatment
(Two Appointments)
• Because your pain has recently increased, you receive
radiation treatment to control cancer cell growth in your
bone and to reduce some of your bone pain.
• You attend a total of two radiation appointments.
• Each radiation appointment lasts about 30 min. During
the procedure, you lie still and experience no pain (like
when getting an x-ray).
• In the area where you receive radiation, your skin
becomes irritated, like getting a sunburn. You also feel
fatigued after the treatment.
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Health state I: basic health state ? surgery to stabilize
bone
• You undergo surgery to stabilize a bone in your leg that
has weakened due to the cancer.
• A metal rod (about 10 cm in length) is inserted into
your leg to stabilize the bone and hold it in place. The
surgery itself is performed at a hospital and lasts
roughly 3 h. You receive general anesthetic for the
surgery.
• You remain in the hospital for about 10 days while you
recover from surgery. After you leave the hospital, you
continue to attend frequent physical therapy (i.e.,
physiotherapy) appointments.
• For the first few weeks after the surgery, you need help
getting up and moving around.
• As you recover from the surgery, you continue to
have some pain and mobility problems for about
3 months.
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